Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2024

Accounting Policies [Abstract]

Schedule of Revenue

For the years ended December 31, 2024, 2023 and 2022, revenue comprised the following:

	Year Ended December 31,
(in thousands)	2024	2023	2022
Prescription transactions revenue	$577,549	$550,738	$550,536
Subscription revenue	86,536	94,410	96,167
Pharma manufacturer solutions revenue (1)	107,237	85,065	99,425
Other revenue	21,002	20,052	20,426
Total revenue	$792,324	$750,265	$766,554

____________________________________________________

(1)Pharma manufacturer solutions revenue for the year ended December 31, 2023 included a $10.0 million contract

termination payment to a pharma manufacturer solutions client in connection with our restructuring activities, which

was recognized as a reduction of revenue. See "Note 17. Restructuring" for additional information.